Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibo...
| Publicado en: | Breast Cancer Research Vol. 23; no. 1; pp. 1 - 12 |
|---|---|
| Autores principales: | , , |
| Formato: | research review Journal Article |
| Publicado: |
BioMed Central
8/11/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |